Silvia Deaglio obtained a Medical Degree magna cum laude from the University of Turin in 1998 with a thesis on the role of human CD38 in health and disease conditions, then trained as a Medical Oncologist (board certification in 2002) and obtained a PhD in Genetics (February 2006). Since 2005 she works independently first as Assistant, then as Associate Professor of Medical Genetics. In 2004-2005 she was Instructor in Medicine and then Visiting Assistant Professor at the Beth Israel Deaconess Medical Center of Harvard University, working on the characterization of the suppressive mechanisms of regulatory T cells. That team was the first to identify adenosine production as an integral component of the suppressive machinery of regulatory T cells. Overall, she is author of more than 105 peer reviewed publications (total IF: 647, h-index: 28). Since 2006 she leads a research team, first at the University of Turin and - since 2010 - at the Human Genetics Foundation (HuGeF, where she has been appointed PI of the Immunogenetics research line by an international Scientific Board (www.hugef-torino.org). She leads a group of 10 researchers. The Unit is dedicated to the understanding and therapeutic manipulation of microenvironmental circuits that favour tumor development and progression. She is financially independent since 2006, managing a total of more than 1 million euros.
Biography Updated on 11 June 2013